A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

NCT01701882 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

St Stephens Aids Trust